Intellia Ends Gene Editing Deal with Regeneron Pharmaceuticals

Intellia Therapeutics (NTLA) has shared an update.

Intellia Therapeutics has decided to withdraw from its 2020 collaboration with Regeneron Pharmaceuticals on developing gene editing treatments targeting factor IX, a coagulation factor. This decision will conclude their shared funding and development responsibilities in six months, although Intellia will still support Regeneron under a previous 2016 agreement, which could yield up to $320 million in milestones and royalties for Intellia. This exit does not impact other ongoing collaborative projects between the two companies.

See more data about NTLA stock on TipRanks’ Stock Analysis page.